Longeveron Inc. (LGVN)
Tests stem cell treatments for heart disease, Alzheimer's, and aging frailty.
$0.61-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-62.9%
The outlook
LGVN is trading near its 52-week low and below both its 50- and 200-day moving averages, indicating sustained downward pressure. Analyst coverage shows a wide gap, with the average price target implying substantial upside from current levels, though the overall sentiment leans bearish. The stock remains in a weak technical position despite the bullish long-term consensus among analysts.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +1079% vs current price
Analyst price target
~12-month · 3 analysts$7.15average target+1078.9% vs now
Now $0.61
Low $3.00High $10.45
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$19.2M
52-wk high
$1.75
52-wk low
$0.48
50-day avg
$0.71
200-day avg
$0.73
Trailing P/E
—